# Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

> **NCT00380068** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 224 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT00380068
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-07
- **Final completion:** 2009-05
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2012-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380068, "Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00380068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*